---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022875"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2026-05-14T12:00:42+00:00"
generated_at: "2026-05-14T12:10:23.339612+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026

## Summary
- Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.
- Net loss $4.8M ($0.41/shr) vs $4.2M ($0.47/shr); operating loss improved to $4.3M from $4.5M.
- Adjusted EBITDA -$3.6M vs -$4.4M; cash consumption near zero; cash $6.3M vs $1.8M Q1 2025.
- FDA accepted sNDA for Ameluz PDT for superficial BCC; PDUFA target date Sept 28, 2026.
- Positive Phase 3 AK results (primary endpoint met) and Phase 2b acne data (58% lesion reduction); regained Nasdaq compliance.

## SEC filing metadata
- accession: 0001493152-26-022875
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2026-05-14T12:00:42+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/0001493152-26-022875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022875
- JSON: https://secwatch.observer/filing/0001493152-26-022875.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.